Masu tsira da ciwon daji suna rayuwa fiye da kowane lokaci, kuma waɗannan suna tsallewa kuma iyakoki suna cikin sashi saboda sababbin magunguna. A yau a Birnin Chicago, a wani taro na kimiyya da ake kira ASCO - taron shekara-shekara na Ƙasar Amirka na Cibiyar Nazarin Kwayoyin Kimiyya - masana masu fama da ciwon daji sun fuskanci kalubalen kalubalen ilimin ilmin halitta.
Suna kuma jin daɗin gaske, kuma a wasu lokuta, tashin hankali.
Rahoton da aka yi a baya ya nuna cewa Gazyva, sabon maganin maganin ciwon daji , yana taimaka wa ƙungiya mai mahimmanci waɗanda ke fama da cutar jinin da aka sani da lymphoma ba Hodgkin, ko NHL.
Game da Lymphoma na Non-Hodgkin
Akwai lymphoma guda biyu: lymphoma Hodgkin da NHL. Kimanin kashi 85 cikin 100 na dukan ilimin lymphomas da aka gano shine NHL. A cewar Cibiyar Cancer na Amurka, ana sa ran kusan mutane 72,000 za a gano su tare da NHL a Amurka a shekarar 2015, kuma kimanin mutane 20,000 zasu mutu daga cutar.
Game da Nazarin
Kyakkyawan zaɓi sun wanzu ga mutanen da ke fama da cutar jini . Duk da haka, kamar yadda masu tsira suka san, wani lokaci ba abin da ya shafi nasara daya ba ne .
Mutane da yawa sun saba da rituximab (Rituxan), da kuma samuwar rayuwa da aka haɗa da yin amfani da irin wadannan kwayoyin halitta - manyan kwayoyin sunadaran sunadarai don magance kwayoyin cutar kanjamau tare da chemotherapy mafi dacewa fiye da chemotherapy kadai.
Binciken da aka gabatar a ASCO ya yi amfani da wani mawallafi guda daya wanda ake kira obinutuzumab wanda FDA ya amince da ita a karkashin sunan cinikin Gazyva tun shekarar 2013 don maganin cutar cutar sankarar lymphocytic na kullum tare da hade da chlorambucil chemotherapy a cikin marasa lafiya.
"Mun haɓaka Gazyva don inganta magunguna na yanzu kuma mun gamsu da yadda ta ba da amfani ga mutanen da suka daina yin biyayya da kulawa," in ji Nancy Valente, MD, Mataimakin Shugaban kasa, Global Hematology Development Genentech.
Nazarin, wanda ake kira binciken GADOLIN, ya nuna yiwuwar Gazyva a cikin wannan wuri. Dokta Valente ya lura cewa shirin zai nemi gayyatar Gazyva a cikin NHL bisa ga waɗannan bayanai kuma suna fatan ganin sakamakon daga wasu manyan manyan littattafan da suke kwatanta shugabancin Gazyva zuwa ɗaya daga cikin mafi girma magunguna.
Marasa lafiya
Masu shiga cikin wannan binciken sun kasance maza da mata da ciwon daji - 413 daga cikinsu. Dukkanansu suna da hanzari ko raunana NHL da suka ci gaba ba tare da jiyya ba. Musamman ma, maganin su sun kasance mai rikitarwa ga tsarin rituximab - wato, rituximab ko rituximab da chemotherapy - wanda ke nufin ciwon su ya ci gaba a lokacin ko cikin watanni shida na wannan magani .
Jiyya
Masu nazarin mahalarta da aka yi amfani da NHL da sauri a cikin kungiyoyi 2 daban daban, don ƙarin magani:
- Gazyva da bendamustine, Gazyva ya biyo baya
- Bendamustine chemotherapy kadai
Sakamako
- Maganin Gazyva na rage yawan hadarin cututtuka ko mutuwa ta kashi 45 cikin dari idan aka kwatanta da chemotherapy kadai.
- An dakatar da binciken ne a farkon lokacin da aka samu gagarumar nasarar da aka samu a cikin kungiyar Gazyva idan aka kwatanta da kungiyar bendamustine - wato, ba zai kasance da ka'ida ba don kiyaye rukuni na bendamustine a kan sakamakon da kungiyar Gazyva ta samu.
Babu wata alamar tsaro da aka sani da Gazyva.
Abin da wannan Ma'anar
Mutumin da ke da lalata maras kyau na NHL yakan wuce ta zagaye na sake dawowa da kuma gafara, kuma za a iya ƙayyade iyaka idan magani na rituximab ya dakatar da aiki. Don haka, sabon haɗin da ke ganin ya yi aiki sosai a cikin marasa lafiya mai kyakwalwa shine labari mai kyau.
"Yawancin mutanen da ke da tausayi na NHL akai-akai sau da yawa, kuma zaɓuɓɓukan magani sun zama ƙananan iyaka da maganganun maganin ba su da tsayuwa a kowane lokacin da cutar ta dawo. Ina ƙarfafawa da bayanai na GADOLIN saboda obinutuzumab da bendamustine wani hade ne wanda ya bayyana. yana da matukar tasiri, "in ji Laurie Sehn, MD, Masanin ilimin likita a asibitin BC Cancer Agency da Farfesa Farfesa a jami'ar British Columbia.
Game da Gazyva
A cikin nazarin lymphoma na yanzu, Gazyva ya ba da lokacin da mutane da masu kyakyawan hankulan NHL suka rayu ba tare da cutar ba. Genentech da Roche, kamfanonin masana kimiyya sun inganta wannan maganin, zasu ba da bayanai daga wannan binciken zuwa hukumomin da ke cikin Amurka, Turai da kuma a duniya domin amincewa da shawara.
Gazyva shi ne wanda aka kirkiro wanda aka kirkiro wanda aka tsara don haɗawa da CD20, mai gina jiki wanda ke samuwa ne kawai a kan sassan B, irin wannan furotin da aka tsara ta rituximab. Gazyva ya rushe kwayoyin CD20 dauke da kai tsaye kuma tare da tsarin rigakafin jiki. Ana zaton Gazyva yana da karfin ikon haifar da mutuwar kwayar halitta ta jiki kuma ya haifar da ƙarin aiki a yadda ake amfani da tsarin kwayoyin jiki na jiki don kai farmaki ga kwayoyin B-kwayoyin cytotoxicity, ko ADCC - idan aka kwatanta da rituximab.
Hanyoyin Gaba da Matsalar Abin Nuna
Lokacin da aka yi amfani da shi kawai, illa ga Gazyva sune, a gaba ɗaya, ƙananan maganganu fiye da illa masu illa ga ma'aikatan chemotherapy. Sakamakon sakamako mafi yawan gaske tare da Gazyva sune halayen jigilar jini, ƙididdigar jini mai ƙananan jini, ƙididdigar ƙananan plats, ƙididdigar jini mai ƙananan jini, zazzabi, tari, tashin zuciya, da kuma zawo.
Gazyva na iya haifar da mummunar haɗari ga al'amuran da suka faru: Hepatitis B maimaitawa, ci gaba mai yawa leukoencephalopathy, ko PML, jiko halayen, ƙwayar cutar ciwon kumburi da cututtuka. Har ila yau, Gazyva na iya haifar da halayen jigilar jigilar jigilar jini, ƙididdigar ƙwayoyin jini da ƙananan ƙwayar plalet wanda zai iya zama mai tsanani ko barazanar rai.
Sources
GADOLIN: Sakamako na farko daga wani nazarin nazarin watanni uku game da obinutuzumab da bendamustine idan aka kwatanta da bendamustine kadai a marasa lafiya tare da rituximab-kyakyawa masu ƙyama wadanda ba Hodgkin lymphoma ba. J Jumma'a Aiki 33, 2015 (Abstract LBA8502).
Magungunan da aka ƙaddamar don cutar cutar sankarar lymphocytic na kullum: ilimin likita na obinutuzumab. Pharmacogenomics da Magungunan Bincike. 2014; Dec 22; 8: 1-7.